Effect of infant immunisation with meningococcus serogroup C-CRM(197) conjugate vaccine on diphtheria immunity and reactogenicity in pre-school aged children.
The majority of Men C conjugate vaccines given in the UK use CRM(197), a mutant diphtheria toxoid, as their protein carrier. We studied the effects of prior immunisation with Men C-CRM(197) conjugate vaccine on immunity to diphtheria in 193 children before and after a booster dose of Men C at 4 years. Baseline diphtheria antibodies were higher in children given four previous doses of Men C (P<0.0001) and tended to be higher following boosting in those who had received three or four doses. This enhanced immunity was not associated with increased reactogenicity.
Department of Paediatrics, Level 4, John Radcliffe Hospital, Headley Way, Headington, Oxon OX20 1XN, UK. jodie.mcvernon@paediatrics.ox.ac.uk
Jodie
J
McVernon
Jenny
J
MacLennan
Elizabeth
E
Clutterbuck
Jim
J
Buttery
E Richard
ER
Moxon
D002675:Child, Preschool; D004165:Diphtheria / Q000276:immunology* / Q000517:prevention & control; D004168:Diphtheria Toxoid / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008589:Meningococcal Infections / Q000276:immunology* / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D015203:Reproducibility of Results; D013997:Time Factors; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
D004168:Diphtheria Toxoid; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate